Overview

• The FDA's decision follows a review that found oral phenylephrine no more effective than a placebo for nasal congestion relief.
• Phenylephrine became a common ingredient in decongestants after pseudoephedrine was restricted due to methamphetamine production concerns.
• The FDA's proposal allows for public comment until May 2025, with a final decision expected thereafter.
• Major U.S. pharmacies have begun removing products containing oral phenylephrine, while Canadian health regulators are reviewing the situation.
• Alternatives for congestion relief include nasal sprays, intranasal steroids, and products with pseudoephedrine, which remain effective.